Sun Pharma Advanced Research Company Limited (SPARC.BO)
INR 124.6
(-1.27%)
INR 124.6
(-1.27%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 755.45 Million INR | -68.36% |
| 2022 | 2.38 Billion INR | 73.98% |
| 2021 | 1.37 Billion INR | -45.74% |
| 2020 | 2.52 Billion INR | 229.31% |
| 2019 | 768.14 Million INR | -57.99% |
| 2018 | 1.82 Billion INR | 133.67% |
| 2017 | 782.58 Million INR | -56.77% |
| 2016 | 1.81 Billion INR | 12.24% |
| 2015 | 1.61 Billion INR | 3.56% |
| 2014 | 1.55 Billion INR | -6.76% |
| 2013 | 1.67 Billion INR | 91.37% |
| 2012 | 872.79 Million INR | 201.21% |
| 2011 | 289.76 Million INR | -50.34% |
| 2010 | 583.47 Million INR | 70.12% |
| 2009 | 342.97 Million INR | -2.4% |
| 2008 | 351.41 Million INR | -6.2% |
| 2007 | 374.62 Million INR | 0.0% |
| 2006 | - INR | 0.0% |
| 2005 | - INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 168.1 Million INR | 1.51% |
| 2024 Q2 | 128.6 Million INR | -23.5% |
| 2023 Q4 | 165.6 Million INR | 19.48% |
| 2023 Q2 | 211.8 Million INR | -11.57% |
| 2023 Q1 | 239.5 Million INR | -49.78% |
| 2023 FY | 755.5 Million INR | -68.36% |
| 2023 Q3 | 138.6 Million INR | -34.56% |
| 2022 FY | 2.38 Billion INR | 73.98% |
| 2022 Q1 | 284.6 Million INR | 12.76% |
| 2022 Q2 | 315.4 Million INR | 10.82% |
| 2022 Q3 | 211.8 Million INR | -32.85% |
| 2022 Q4 | 476.9 Million INR | 125.17% |
| 2021 FY | 1.37 Billion INR | -45.74% |
| 2021 Q1 | 219.9 Million INR | -21.62% |
| 2021 Q3 | 621.5 Million INR | 123.0% |
| 2021 Q2 | 278.7 Million INR | 26.74% |
| 2021 Q4 | 252.38 Million INR | -59.39% |
| 2020 FY | 2.52 Billion INR | 229.31% |
| 2020 Q1 | 1.85 Billion INR | 716.8% |
| 2020 Q2 | 176.4 Million INR | -90.49% |
| 2020 Q3 | 218.1 Million INR | 23.64% |
| 2020 Q4 | 280.57 Million INR | 28.64% |
| 2019 FY | 768.14 Million INR | -57.99% |
| 2019 Q1 | 173.2 Million INR | -79.58% |
| 2019 Q4 | 227.04 Million INR | 15.84% |
| 2019 Q3 | 196 Million INR | 14.02% |
| 2019 Q2 | 171.9 Million INR | -0.75% |
| 2018 Q1 | 168.1 Million INR | -16.33% |
| 2018 FY | 1.82 Billion INR | 133.67% |
| 2018 Q4 | 848.29 Million INR | 326.71% |
| 2018 Q3 | 198.8 Million INR | -67.6% |
| 2018 Q2 | 613.5 Million INR | 264.96% |
| 2017 Q1 | 233.9 Million INR | -43.77% |
| 2017 FY | 782.58 Million INR | -56.77% |
| 2017 Q4 | 200.9 Million INR | 3.45% |
| 2017 Q3 | 194.2 Million INR | 26.43% |
| 2017 Q2 | 153.6 Million INR | -34.33% |
| 2016 Q3 | 230.5 Million INR | -75.71% |
| 2016 FY | 1.81 Billion INR | 12.24% |
| 2016 Q4 | 416 Million INR | 80.48% |
| 2016 Q2 | 948.9 Million INR | 341.76% |
| 2016 Q1 | 214.8 Million INR | -47.83% |
| 2015 Q3 | 335.5 Million INR | -22.19% |
| 2015 Q2 | 431.2 Million INR | -0.74% |
| 2015 Q4 | 411.7 Million INR | 22.71% |
| 2015 FY | 1.61 Billion INR | 3.56% |
| 2015 Q1 | 434.4 Million INR | 1.74% |
| 2014 Q4 | 426.97 Million INR | 36.5% |
| 2014 FY | 1.55 Billion INR | -6.76% |
| 2014 Q3 | 312.8 Million INR | -31.87% |
| 2014 Q2 | 459.1 Million INR | 28.06% |
| 2014 Q1 | 358.5 Million INR | -15.79% |
| 2013 Q4 | 425.69 Million INR | -32.38% |
| 2013 FY | 1.67 Billion INR | 91.37% |
| 2013 Q2 | 258.4 Million INR | -27.56% |
| 2013 Q1 | 356.7 Million INR | -50.34% |
| 2013 Q3 | 629.5 Million INR | 143.61% |
| 2012 Q1 | 63.8 Million INR | 51.31% |
| 2012 Q3 | 42.2 Million INR | -12.99% |
| 2012 Q4 | 718.29 Million INR | 1602.11% |
| 2012 FY | 872.79 Million INR | 201.21% |
| 2012 Q2 | 48.5 Million INR | -23.98% |
| 2011 Q3 | 45.1 Million INR | 0.0% |
| 2011 FY | 289.76 Million INR | -50.34% |
| 2011 Q4 | 42.16 Million INR | -6.51% |
| 2010 FY | 583.47 Million INR | 70.12% |
| 2009 FY | 342.97 Million INR | -2.4% |
| 2008 FY | 351.41 Million INR | -6.2% |
| 2007 FY | 374.62 Million INR | 0.0% |
| 2006 FY | - INR | 0.0% |
| 2005 FY | - INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bal Pharma Limited | 3.39 Billion INR | 77.73% |
| Achyut Healthcare Limited | 61.36 Million INR | -1131.001% |
| Alkem Laboratories Limited | 126.67 Billion INR | 99.404% |
| Divi's Laboratories Limited | 78.45 Billion INR | 99.037% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 99.36% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 96.691% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -49.828% |
| Mankind Pharma Limited | 103.34 Billion INR | 99.269% |
| Medicamen Biotech Limited | 1.79 Billion INR | 57.868% |
| Medico Remedies Limited | 1.44 Billion INR | 47.871% |
| Megasoft Limited | 373.95 Million INR | -102.018% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 93.438% |
| Piramal Pharma Limited | 81.71 Billion INR | 99.075% |
| Sequent Scientific Limited | 13.69 Billion INR | 94.485% |
| Sigachi Industries Limited | 3.98 Billion INR | 81.064% |
| Ajanta Pharma Limited | 42.08 Billion INR | 98.205% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.844% |
| Brooks Laboratories Limited | 794.86 Million INR | 4.958% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 95.839% |
| Themis Medicare Limited | 3.81 Billion INR | 80.211% |
| Unichem Laboratories Limited | 16.57 Billion INR | 95.442% |
| Hester Biosciences Limited | 3.04 Billion INR | 75.194% |
| Venus Remedies Limited | 5.91 Billion INR | 87.227% |
| Indoco Remedies Limited | 17.89 Billion INR | 95.778% |
| Ind-Swift Limited | 5.02 Billion INR | 84.965% |
| Aarti Drugs Limited | 25.28 Billion INR | 97.012% |
| Alpa Laboratories Limited | 1.08 Billion INR | 30.526% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 94.169% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.729% |
| Granules India Limited | 45.06 Billion INR | 98.324% |
| Gufic Biosciences Limited | 8.06 Billion INR | 90.635% |
| Hikal Limited | 17.84 Billion INR | 95.767% |
| RPG Life Sciences Limited | 5.82 Billion INR | 87.021% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 92.814% |
| Windlas Biotech Limited | 6.3 Billion INR | 88.027% |
| ZIM Laboratories Limited | 3.67 Billion INR | 79.439% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 94.102% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 96.435% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 98.873% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 99.737% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 84.043% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -88.697% |
| Ipca Laboratories Limited | 76.22 Billion INR | 99.009% |
| Lasa Supergenerics Limited | 1.04 Billion INR | 27.594% |
| Laurus Labs Limited | 50.01 Billion INR | 98.49% |
| NATCO Pharma Limited | 40.02 Billion INR | 98.112% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 95.514% |
| Shilpa Medicare Limited | 11.51 Billion INR | 93.44% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 93.9% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 99.288% |
| Wanbury Limited | 5.75 Billion INR | 86.877% |
| Wockhardt Limited | 27.89 Billion INR | 97.291% |
| Strides Pharma Science Limited | 40.51 Billion INR | 98.135% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 90.192% |
| Suven Life Sciences Limited | 116.92 Million INR | -546.078% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 82.066% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 98.764% |
| Eris Lifesciences Limited | 20.09 Billion INR | 96.24% |
| Lupin Limited | 200.1 Billion INR | 99.622% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 70.859% |
| Valiant Laboratories Limited | 1.82 Billion INR | 58.505% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.603% |
| FDC Limited | 19.42 Billion INR | 96.112% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 97.832% |
| Novartis India Limited | 3.35 Billion INR | 77.454% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 63.802% |
| Neuland Laboratories Limited | 15.58 Billion INR | 95.153% |
| Morepen Laboratories Limited | 17.01 Billion INR | 95.561% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | 51.063% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | 79.505% |